BOSTON, Nov. 2 /PRNewswire/ -- Surface Logix Inc. announced today that the Company’s lead clinical candidate, SLx-2101, has been selected as one of the top ten most promising cardiovascular drugs in development, offering significant potential for strategic partnering. SLx-2101 is an oral selective, fast-onset, long-acting (48 hour) PDE-5 inhibitor designed specifically to expand the therapeutic potential of PDE-5 inhibition beyond erectile dysfunction into larger cardiovascular markets. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
“Selected companies have been screened using a strict set of judging criteria for the top ten award, and represent what our committee considered the most attractive cardiovascular licensing opportunities the industry has to offer,” stated Roger Longman of Windhover Information.
“It is an honor to be chosen by this respected group of industry professionals, and we welcome the independent validation of SLx-2101,” said Jim Mahoney, Surface Logix President and Chief Executive Officer. “We are currently investigating SLx-2101 in Phase II clinical trials and believe it will fulfill the original promise of PDE5 inhibition in cardiovascular disease including hypertension and Raynaud’s disease.”
The selection committee was led by Marc Wortman, PhD, contributing writer to Windhover’s In Vivo and Start Up, and Ed Saltzman, president of Defined Health, a leading business development strategy consulting firm. Drawing on the analytic resources of both organizations, the group evaluated hundreds of compounds currently in development for the treatment of cardiovascular disease prior to selecting SLx-2101 among the top ten most attractive.
The evaluation which ranked SLx-2101 among this top echelon measured a number of factors including:
-- Unmet medical need -- Market potential -- Multi-level partnering opportunities (biotech and pharma) -- Potential for new opportunities beyond initial indications -- Diversity of indications -- History of the molecule and drug -- Strong science -- Strong company
As a selected company, Surface Logix has been invited to present data on SLx-2101 at Windhover’s Therapeutic Alliances Cardiovascular Conference in Chicago on November 16th, immediately following the American Heart Association (AHA) Conference.
About SLx-2101
SLx-2101 was designed using Surface Logix’s proprietary chemistry platform, the Pharmacomer Technology Platform to have a combination of potency, selectivity, tissue distribution and half-life which optimizes its potential for once daily utility in the vascular tissues involved in major cardiovascular diseases. The clinical experience of SLx-2101 to date establishes the PK range of the PDE5 inhibitor as well as demonstrating efficacy in established models of endothelial function (peripheral arterial tone and erectile function). Additional Phase II studies in cardiovascular indications are scheduled for Q4, 2006.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Contact: Warwick Tong Senior Vice President, Commercial Development wtong@surfacelogix.com 617.746.8500 Media: Kari Watson MacDougall Biomedical Communications Inc. kwatson@macbiocom.com 508.647.0209
Surface Logix Inc.
CONTACT: Warwick Tong, Senior Vice President, Commercial Development of+1-617-746-8500, wtong@surfacelogix.com; or Media: Kari Watson ofMacDougall Biomedical Communications Inc., +1-508-647-0209,kwatson@macbiocom.com
Web site: http://www.surfacelogix.com/
